BLAINJECTIONINJECTABLE
Approved
Apr 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
5/8 — Partial
ALYMSYS (bevacizumab-maly) by Amneal Pharms is vascular endothelial growth factor-directed antibody interactions [moa]. First approved in 2022.
Drug data last refreshed 2h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALYMSYS (bevacizumab-maly) is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis. It is a biosimilar to the reference bevacizumab product, approved in April 2022. The drug is indicated for VEGF-driven cancers where anti-angiogenic therapy is standard of care.
$0.486MPart D
PeakAs a biosimilar in peak lifecycle phase with modest Part D penetration, the brand team is likely focused on market access and physician adoption against reference and competing biosimilar entrants.
Mechanism of Action
Vascular Endothelial Growth Factor-directed Antibody Interactions
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on ALYMSYS at Amneal Pharms? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.